If you are reading this, there is a reasonable chance you have just had a difficult conversation, or you are about to have one. A cancer diagnosis brings a long list of questions in the same week: what type, how advanced, what treatment, how soon, and increasingly in 2026, how long the wait will be. This guide walks through the six most commonly diagnosed cancers in the UK, what current treatment looks like, and what changes when the wait is too long for comfort.
The numbers that frame everything: more than 403,000 new cancer cases are diagnosed in the UK every year, around 1,100 every day, with around 170,000 cancer deaths. Almost half of people born in the UK in 1961 will be diagnosed with cancer at some point in their lifetime. Roughly half of patients diagnosed today will survive ten years or more, the highest survival rate the UK has ever recorded.
How cancer care in the UK works in 2026
Most pathways start the same way: a worrying symptom, a GP appointment, an urgent suspected cancer referral on what used to be called the two-week-wait pathway. Since October 2023 the NHS in England has measured cancer performance against three standards: a 28-day Faster Diagnosis Standard (75 per cent target), a 31-day decision-to-treatment target (96 per cent), and an overarching 62-day referral-to-first-treatment target (85 per cent).
The Faster Diagnosis Standard is being met most months. The 31-day target has slipped to around 91 per cent. The headline 62-day target is the one that has stalled. In September 2024 only 67 per cent of patients began treatment within 62 days of urgent referral, leaving more than 8,000 patients waiting over two months to start. The 85 per cent target has not been met since 2013/14. A target alone does not move a tumour, and for many patients these waits coincide with the period when treatment decisions matter most.
The UK has the resources, the surgeons and the protocols. What it does not always have, in 2026, is enough capacity to start treatment when it should start. That gap is what now drives a small but growing number of UK patients to look at private care or treatment abroad.
1. Breast cancer: the most common UK cancer
Breast cancer is the single most commonly diagnosed cancer in the UK. UK cancer registry data records 60,763 new cases in women, accounting for 30.2 per cent of all female cancers. Around 500 men a year are also diagnosed.
Most cases are detected through the NHS breast screening programme (mammography for women aged 50 to 71), through GP referral after a lump or change is noticed, or after symptoms such as nipple discharge or skin changes. Treatment is well established: surgery (lumpectomy or mastectomy), often followed by radiotherapy, with chemotherapy, hormone therapy (for ER-positive disease) and HER2-targeted therapy used depending on the cancer's biology. Reconstruction is usually offered, although timing varies by trust.
Survival is among the best of any common cancer: more than 95 per cent of women diagnosed survive at least one year, and 5-year survival exceeds 85 per cent for early-stage disease. The catch is the gap between best case and average case; late-stage disease, or treatment delayed past the 62-day target, materially worsens outcomes. For UK patients facing waiting-list delays or affordability barriers to UK private care, the MediVenza breast cancer treatment package in India starts from $5,000 USD and includes the full surgical and reconstructive pathway at JCI-accredited hospitals.
2. Prostate cancer: the most common cancer in UK men
Prostate cancer is the most commonly diagnosed cancer in UK men, with 68,218 cases recorded in the most recent data, around 30.6 per cent of all male cancers. There is no national screening programme; diagnosis usually follows a raised PSA result, urinary symptoms, or family-history-prompted testing.
The clinical picture is unlike most other cancers. Many cases are slow-growing and never need active treatment. Active surveillance, where low-risk cancers are monitored rather than treated, is now standard for suitable patients. When treatment is needed, options include radical prostatectomy (often robotically assisted), external beam radiotherapy, brachytherapy, hormone therapy, and for advanced disease, chemotherapy and newer agents such as enzalutamide and abiraterone.
One-year survival exceeds 95 per cent and 5-year survival is above 85 per cent, the highest of any common UK cancer. Most men diagnosed with prostate cancer in the UK will not die of it. Where decisions get harder is the side-effect profile of treatment: incontinence and erectile dysfunction are real risks of both surgery and radiotherapy, and surgical volume matters. India's leading hospitals routinely perform robotic-assisted radical prostatectomies at JCI-accredited centres, with packages at a fraction of UK private prices.
3. Lung cancer: the third most common, the most lethal
Lung cancer is the third most common cancer in the UK, with 51,314 new cases combined, accounting for around 12 per cent of new cases. It also kills more people than any other cancer in the UK, responsible for around one in five cancer deaths. The reason is stage at diagnosis: roughly 6 in 10 lung cancers are picked up at an advanced stage, when curative treatment is no longer realistic.
Lung cancer splits into two main types. Non-small-cell lung cancer (NSCLC) accounts for around 85 per cent of cases and is treated with surgery, radiotherapy, chemotherapy, immunotherapy (such as pembrolizumab) or targeted therapy where a driver mutation (EGFR, ALK, ROS1) is identified through genomic testing. Small-cell lung cancer (SCLC), the rest, is more aggressive and treated primarily with chemotherapy and radiotherapy. The NHS has rolled out targeted lung health checks in some areas, with low-dose CT screening for high-risk patients beginning to detect more early-stage cancers.
Five-year survival for early-stage lung cancer is around 60 per cent. For stage 4 lung cancer in men it is around 3.5 per cent. Stage at diagnosis is everything, which is why time to first treatment matters more here than in slower-growing cancers. The MediVenza lung cancer treatment pathway through Apollo, Fortis or Medanta gives access to the same staging investigations, surgical resections, modern radiotherapy and immunotherapy regimens, with treatment typically starting within days of arrival.
4. Bowel cancer: the fourth most common
Bowel cancer (colorectal cancer) is the fourth most common UK cancer, with 49,364 new cases according to the most recent data. It is the second-largest cause of cancer death after lung cancer. The NHS bowel cancer screening programme (FIT home test, biennial, ages 54 to 74 and being expanded down to age 50) catches a significant share of cases at an early, highly treatable stage.
Treatment depends on stage. Early bowel cancers are often removed entirely during a colonoscopy or with a limited surgical resection. More advanced cancers require formal bowel resection (laparoscopic or open), often with neoadjuvant or adjuvant chemotherapy. Rectal cancer is usually treated with combined chemo-radiotherapy before surgery. Liver and lung metastases, where present and limited, are increasingly resected rather than just managed palliatively.
One-year survival is around 80 per cent and 5-year survival, all stages combined, is around 60 per cent. Stage 4 disease remains hard to cure. Indian centres routinely perform laparoscopic and robotic bowel cancer resections. For patients on a long elective surgical waiting list, a self-funded route becomes worth pricing; MediVenza runs a free 24-hour assessment with the actual surgical team that would treat you.
5. Bladder cancer: the fifth most common
Bladder cancer is the fifth most common UK cancer overall and the seventh most common in men, with around 10,500 new cases a year recorded by UK cancer registries. Charity counts that include very early-stage non-muscle-invasive cases run higher. Bladder cancer is the only top-10 UK cancer where survival has not meaningfully improved over the last 40 years.
The most common presenting symptom is blood in the urine (haematuria). Diagnosis is by cystoscopy and biopsy. Treatment depends on whether the cancer is non-muscle-invasive (transurethral resection, or TURBT, plus intravesical BCG or chemotherapy) or muscle-invasive (radical cystectomy with urinary diversion, or radical radiotherapy with chemotherapy as a bladder-preserving alternative). Five-year survival for early-stage disease is around 80 per cent, but falls steeply for advanced disease.
Radical cystectomy is a major operation with significant lifestyle impact, and surgical experience matters. For UK patients facing a long wait or wanting a faster path to surgery, India's high-volume urological oncology centres offer the same procedures, including robotic radical cystectomy.
6. Melanoma: the sixth most common, and rising fast
Melanoma skin cancer is the sixth most common cancer in the UK, with around 19,700 cases a year. Among the 20 most common cancers it has shown the fastest increase in incidence over the past decade. The UK has higher melanoma incidence than most of Europe, partly explained by sun exposure patterns in fair-skinned populations.
Most melanomas are diagnosed early after a mole change is noticed, biopsied and confirmed. Stage 1 melanoma has 5-year survival above 95 per cent. Treatment for early disease is wide local excision; for cancers with deeper invasion, sentinel lymph node biopsy and possibly lymph node dissection. For advanced or metastatic melanoma, the picture has been transformed in the last decade by checkpoint immunotherapy (pembrolizumab, nivolumab, ipilimumab) and BRAF/MEK targeted therapy for patients with the BRAF V600 mutation.
Routine NHS care for early melanoma is generally on time. Where India becomes relevant is in advanced-stage cases where access to combination immunotherapy or sequential targeted therapy is being delayed by funding decisions, or where a patient wants a second opinion plus a treatment plan delivered through a JCI-accredited oncology centre.
NHS, UK private and India: the honest comparison
What you are comparing | NHS | UK private | India (MediVenza partner hospitals) |
|---|---|---|---|
Cost to patient | Free at point of use | Self-funded; cancer pathways often Ā£30,000 to Ā£100,000+ | Surgical packages from $5,000 USD; full pathways costed before travel |
Time to first treatment | 62-day target; around 1 in 3 missed it as of late 2024 | Usually 1 to 3 weeks | Usually 1 to 2 weeks from arrival |
Surgical and clinical quality | High; UK surgeons and protocols among the world's best | Same surgeons, often the same hospitals | JCI-accredited; Western-trained consultants; high case volumes |
Continuity of care after treatment | Full NHS follow-up | Private follow-up or hand-back to NHS | Remote follow-up plus hand-back to UK GP or oncologist |
When does going to India actually make sense?
For most UK cancer patients, the right answer is to start NHS treatment as soon as the system can begin it. India is not a replacement for the NHS. It is a serious option in three specific situations:
The wait is too long: if your 62-day clock is at week 8 with no surgical date, a self-funded route in the UK or India becomes worth pricing.
UK private is unaffordable: a Ā£40,000 to Ā£80,000 private UK cancer pathway is real money. India's cost is typically 60 to 70 per cent lower, including accommodation and care coordination.
You want a second opinion plus a treatment plan together: Indian oncology MDTs review your imaging and reports before you travel, so you arrive with a plan, not a question.
If you have a UK cancer diagnosis and the NHS pathway is moving, stay on it; cancer care here at its best is genuinely excellent. If the wait is making you anxious, or the private UK quote is unaffordable, it is worth seeing what an Indian package looks like before writing off the option. MediVenza will review your scans and reports through partner oncology teams and come back with a written assessment, costed and timed, within 24 hours. You can reach the team via the contact page or on WhatsApp at +91 98996 55596. There is no commitment to travel; many patients use the assessment simply to decide whether their UK pathway is reasonable.
